Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality
Hong Zhang, … , Stefan Rose-John, Hana Algül
Hong Zhang, … , Stefan Rose-John, Hana Algül
Published February 15, 2013
Citation Information: J Clin Invest. 2013;123(3):1019-1031. https://doi.org/10.1172/JCI64931.
View: Text | PDF
Research Article Immunology

IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality

  • Text
  • PDF
Abstract

Acute lung injury (ALI) is an inflammatory disease with a high mortality rate. Although typically seen in individuals with sepsis, ALI is also a major complication in severe acute pancreatitis (SAP). The pathophysiology of SAP-associated ALI is poorly understood, but elevated serum levels of IL-6 is a reliable marker for disease severity. Here, we used a mouse model of acute pancreatitis–associated (AP-associated) ALI to determine the role of IL-6 in ALI lethality. Il6-deficient mice had a lower death rate compared with wild-type mice with AP, while mice injected with IL-6 were more likely to develop lethal ALI. We found that inflammation-associated NF-κB induced myeloid cell secretion of IL-6, and the effects of secreted IL-6 were mediated by complexation with soluble IL-6 receptor, a process known as trans-signaling. IL-6 trans-signaling stimulated phosphorylation of STAT3 and production of the neutrophil attractant CXCL1 in pancreatic acinar cells. Examination of human samples revealed expression of IL-6 in combination with soluble IL-6 receptor was a reliable predictor of ALI in SAP. These results demonstrate that IL-6 trans-signaling is an essential mediator of ALI in SAP across species and suggest that therapeutic inhibition of IL-6 may prevent SAP-associated ALI.

Authors

Hong Zhang, Patrick Neuhöfer, Liang Song, Björn Rabe, Marina Lesina, Magdalena U. Kurkowski, Matthias Treiber, Thomas Wartmann, Sara Regnér, Henrik Thorlacius, Dieter Saur, Gregor Weirich, Akihiko Yoshimura, Walter Halangk, Joseph P. Mizgerd, Roland M. Schmid, Stefan Rose-John, Hana Algül

×

Figure 8

Pharmacological inhibition of STAT3, CXCR2, CXCL1, and IL-6 trans-signaling attenuates SAP-induced lethal ALI.

Options: View larger image (or click on image) Download as PowerPoint
Pharmacological inhibition of STAT3, CXCR2, CXCL1, and IL-6 trans-signal...
(A) Kaplan-Meier curves of C57BL/6 mice (black; n = 11) and C57BL/6 mice treated with the CXCR2 antagonist SB225002 (green; n = 12), the STAT3 inhibitor S3I-201 (red; n = 7), recombinant sgp130Fc (blue; n = 8), or an anti-CXCL1 antibody (orange; n = 5) during SAP. (B and C) Serum was removed for amylase and lipase analyses at the indicated time points (n = 4). (D) MPO activity in lung tissue of C57BL/6 mice or treated mice 8 hours after the first cerulein injection (n = 4). (E and F) Histological sections of pancreatic and lung tissue. Note the decrease in lung injury in treated versus C57BL/6 mice. **P < 0.005 versus control. Scale bars: 50 μm (E); 100 μm (F).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts